Who are Growth Hormones Somatropin Recombinant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): MAXOMAT ®, biosynthetic growth hormone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/growth-hormones-somatropin-recombinant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Growth Hormones Somatropin Recombinant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Growth Hormones Somatropin Recombinant (Growth Hormones Somatropin Recombinant) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone (recombinant human growth hormone). Area: Endocrinology.

marketed Growth hormone (recombinant human growth hormone) Growth hormone receptor (GHR) Endocrinology Small molecule Live · refreshed every 30 min

Target snapshot

Growth Hormones Somatropin Recombinant (Growth Hormones Somatropin Recombinant) — ClinAmygate. Somatropin is a recombinant human growth hormone that binds to growth hormone receptors to stimulate growth, metabolism, and body composition changes.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Growth Hormones Somatropin Recombinant TARGET	Growth Hormones Somatropin Recombinant	ClinAmygate	marketed	Growth hormone (recombinant human growth hormone)	Growth hormone receptor (GHR)
MAXOMAT ®, biosynthetic growth hormone	MAXOMAT ®, biosynthetic growth hormone	Sanofi	phase 3	Growth hormone (recombinant human growth hormone)	Growth hormone receptor (GHR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone (recombinant human growth hormone) class)

ClinAmygate · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Growth Hormones Somatropin Recombinant — Competitive Intelligence Brief. https://druglandscape.com/ci/growth-hormones-somatropin-recombinant. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab